Core Insights - Innovent's partner Ollin Biosciences announced final data from the Phase 1b JADE clinical study, showing that OLN324 outperformed faricimab in treating diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) [1][9] Study Results - The JADE trial enrolled 164 patients, comparing OLN324 to faricimab, with all patients receiving three monthly doses followed by a 12-week follow-up [3][11] - At Week 20, OLN324 demonstrated greater retinal drying in DME patients compared to faricimab, with sustained vision gains [4][5] - In wAMD, OLN324 showed rapid and comparable improvements in retinal drying, with a mean visual acuity gain of +2.2 letters over faricimab at Week 20 [6][8] Safety Profile - OLN324 maintained a favorable safety profile, with no cases of intraocular inflammation, while faricimab had one case [7][9] Future Developments - Ollin and Innovent plan to advance OLN324 into global Phase 3 studies in DME and wAMD in 2026, targeting recruitment from multiple regions including North America, Europe, and Asia [9][12]